VivoSeq
Oncology

Lung Neoplasm

25

Pipeline Programs↗

2

Active Trials↗

15

Companies Involved↗

Lung Neoplasm is an emerging landscape with 25 programs across 15 companies. The most active players are Merck & Co., Gynecologic Oncology Group, Innovent Biologics (Suzhou) Co. Ltd.. 12 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

49/100

Pipeline Velocity

0/100

Mech. Concentration

13/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

4 programs

Phase 2G

Gynecologic Oncology Group

1 program

Phase 2Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.

1 program

Phase 2T

Tracon Pharmaceuticals Inc.

1 program

Phase 2G

German Society for Pediatric Oncology and Hematology GPOH gGmbH

1 program

Phase 2Roche logo

Roche

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

77%

Small molecule

17 of 22 classified programs — the dominant modality here.

23%ALL OTHERSMonoclonal antibody523%

Small molecule leads; the ring shows all 22 classified programs, each share of the total. Modality classified for 92% of 25 pipeline programs.

Analysis

Trial Status

2

clinical trials

Recruiting1 · 50%
Active, not recruiting1 · 50%

Clinical Trials

Trial Activity

KEYMAKER-U01 Substudy 01I: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC)
Recruiting·Merck & Co. logoMerck & Co.·Phase 2·NCT06780098·144 enrolled
Quantitative Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and Melanoma Undergoing Standard-of-Care FDG-PET/CT for Initial Staging
Active, not recruiting·UUniversity of California, Davis·Preclinical·NCT04478318·180 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)